Pulmonary Hypertension
Conditions
Brief summary
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.
Detailed description
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment. Patients had a cardiac ultrasound scan prior to the introduction of carfilzomib and an ultrasound scan following the introduction of carfilzomib. We will look at the evolution of right ventricular function parameters in these patients.
Interventions
None listed
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients treated for multiple myeloma with carfilzomib * Patients with echocardiogram before and under treatment.
Exclusion criteria
* /
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tricuspid annular plane systolic excursion | 6 months after carfilzomib treatment | measurement of tricuspid annular plane systolic excursion by echocardiography |
Countries
France
Outcome results
None listed